Search
-
Patient Enrollment Completed for BA9101 Phase 3 Clinical Study
Boan Biotech today announced that patient enrollment has been completed for the Phase 3 clinical study (comparative clinical study of efficacy and safety) of BA9101 (Aflibercept Intravitreous Injectio...
2023-03-14
MORE>
-
Luye Pharma Receives Clinical Trial Approval in Europe for Its Innovative Formulation Paliperidone Palmitate Long-acting Injection LY03010
Shanghai, February 23, 2023 - Luye Pharma Group today announced that it has received the approval by the competent authorities to initiate the first clinical trial in Europe for its Paliperidone Palmi...
2023-02-24
MORE>
-
FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder
Rykindo® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s Central Nervous System (CNS) product portfolio to be marketed in the United State...
2023-01-16
MORE>
-
Luye Pharma’s Innovative Anti-Cancer Therapy Lurbinectedin to Benefit “Named Patients” in Hong Kong
January 9, 2023 – Luye Pharma Group today announced the launch of the Named Patient Program (NPP) in Hong Kong, China, providing eligible local patients immediate access to the innovative anti-c...
2023-01-09
MORE>
-
Boan Biotech’s First Investigational ADC, BA1301 for Injection, Approved for Clinical Trials in China
January 09, 2023 - Luye Pharma Group announced today that BA1301 for injection, an innovative antibody-drug conjugate (ADC) candidate developed by its subsidiary Boan Biotech, has been approved for cl...
2023-01-09
MORE>
-
Boan Biotech Officially Listed on the Main Board of SEHK Accelerating to Become a Leading Global Biopharmaceutical Company
(30 December 2022, Hong Kong, China)Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech” or the “Company”), a subsidiary of Luye Pharma Group, was officially listed on the Main Board of the Stock...
2023-01-03
MORE>
-
Luye Pharma’s Innovative Formulation LY03010 Meets Endpoints in Pivotal U.S. Study
November 21, 2022 - Luye Pharma Group announced today that a pivotal study conducted in the U.S. for the company's in-house developed innovative formulation, Paliperidone Palmitate Extended-releas...
2022-11-22
MORE>
-
China’s First Denosumab Biosimilar Boyoubei® Approved for Launch by NMPA
Luye Pharma Group today announced that Denosumab Injection (Boyoubei®) developed by its subsidiary Boan Biotech has been approved for launch in China by the National Medical Products Administration (N...
2022-11-11
MORE>
-
Luye Pharma’s Class 1 Innovative Antidepressant Ruoxinlin® Approved for Launch in China
November 3, 2022 – Luye Pharma Group today announced that Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), its innovative drug for treating Major Depressive Disorder (MDD)...
2022-11-03
MORE>
-
Boan Biotech’s BA2101 Injection Approved for Clinical Trials in China
October 27, 2022 -- Luye Pharma Group announced today that BA2101 has been approved by the Center for Drug Evaluation of the National Medical Products Administration for clinical trials in China. This...
2022-10-28
MORE>
var _hmt = _hmt || [];
(function() {
var hm = document.createElement("script");
hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864";
var s = document.getElementsByTagName("script")[0];
s.parentNode.insertBefore(hm, s);
})();
!function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
one体育-艾尚体育
沐鸣平台_沐鸣平台科技_沐鸣平台厂家_沐鸣平台企业
力量体育app_官网-力量体育app
one体育-官网app下载
im电竞官网app